Targeted protein stability Vicinitas Therapeutics specializes in Deubiquitinase Targeting Chimeras (DUBTACs) to stabilize disease-relevant proteins previously deemed undruggable, presenting a clear cross-sell opportunity with protein stabilization platforms for biotech collaborators and large pharma seeking novel modality approaches.

Strategic financing leverage With a $65M Series A securing capital and a focus on precision medicines, engaging potential investors, strategic partners, and governance allies could unlock co-development, milestone-based collaborations, and access to follow-on funding rounds.

Early-stage opportunity Small team size (2-10 employees) and pre-revenue status indicate high flexibility for partnering with bigger CROs, contract research, and joint ventures to accelerate lead optimization, translational studies, and IND-enabling activities.

Academic-industry pedigree Originating from Novartis Institutes for BioMedical Research and UC Berkeley, the company carries an established scientific credibility, enabling targeted outreach to academic consortiums, biotech accelerators, and licensed collaboration talks to access cutting-edge research resources.

Biotech ecosystem fit Located in South San Francisco with cloud-based tech stack and scalable data practices, Vicinitas can leverage regional biotech networks, CROs, and contract manufacturing organizations for rapid prototyping, data collaboration, and streamlined regulatory preparation.